Is there still a room for crizotinib in first-line setting in ALK-positive NSCLC patients?

26 / 39

After crizotinib…
Certinib Brigatinib
Alectinib Lorlatinib
Crizo +/- 1-2 CT
N=59
Crino – JCO 2017 * Kim – JCO 2017 * Camidge – JCO 2018 * Shaw – Lancet Oncol 2016 * Gadgeel –JCO 2016 * Camidge – JCO 2018 * Besse – ASCO 2018
RR 73%. PFS 11.1 mo. icRR: 70%
ASCEND 2
N=140
RR 39%. PFS 5.7 mo. icRR: 45%
RR 48%. PFS 8.1 mo. icRR: 62%*
NPS28673
N=87
*Pooled
RR 54%. PFS 12.9 mo.
icRR: 67%. icPFS: 18.4 mo.
N=220
90à180 mg
ALUR ph III trial (BICR): RR:38%, PFS 7.1 mo., icRR: 54%
ASCEND5 ph III trial: RR:39%, PFS 5.4 mo., icRR: 35%